drugset / Trial / NCT02992132
Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy of pimavanserin compared with placebo in treatment of agitation and aggression after 12 weeks of treatment
Timeline
- Start
- 2016-11
- Primary completion
- 2018-01-25
- Completion
- 2018-02-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimavanserin | Small molecule | 20 mg | Oral |
| Subject | Pimavanserin | Small molecule | 34 mg | Oral |
Indications
No indication recorded.